海利生物(603718.SH):2名監事及高管擬減持不超12.245萬股
格隆匯2月14日丨海利生物(603718.SH)公佈,截至本公告日,公司監事周裕生持有公司股份36.3萬股,佔公司股份總數的0.0564%。公司副總裁劉漢平持有公司股份12.68萬股,佔公司股份總數的0.0197%。
周裕生和劉漢平因個人資金需要,計劃自本公告披露之日起十五個交易日後的六個月內(窗口期等期間不得減持股份),將通過上海證券交易所集中競價交易的方式進行減持。周裕生減持不超過9.075萬股的公司股份,佔公司股份總數的比例不超過0.0141%;劉漢平減持不超過3.17萬股,佔公司股份總數的比例不超過0.0049%。若上述減持期間公司有送股、資本公積金轉增股本、配股等事項,減持股份數量將相應調整。減持價格將按照減持實施時的市場價格確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.